文献速递心力衰竭与心肌病

高通量血浆蛋白质组学与晚年心力衰竭及衰弱风险

High Throughput Plasma Proteomics and Risk of Heart Failure and Frailty in Late Life.
PubMed 文献 · JAMA Cardiol · 2024-01-01

48个与V5时衰弱患病相关,18个与V6新发衰弱相关。这些蛋白富集纤维化和炎症通路,与HFpEF关联更强,孟德尔随机化提示部分蛋白可能对衰弱和心衰有因果效应。

要点

  • 炎症和纤维化通路是心衰与衰弱共享的病理生理机制。
  • 多个蛋白与HFpEF的关联强于HFrEF。
  • 部分蛋白经孟德尔随机化提示对衰弱和心衰有潜在因果效应。

核心结论

  • 与心衰和衰弱风险相关的蛋白富集炎症和纤维化通路,并与HFpEF风险相关。
  • 部分蛋白可能参与衰弱和心衰的共同病理生理。

研究设计与样本

  • 在CHS的3189名参与者中进行外部重复验证。
  • 采用Fried标准评估衰弱,并进行孟德尔随机化分析。

主要发现

  • 286个蛋白与V3后新发心衰相关(822例事件,P<1.0×10⁻⁵),其中83个也与V5后新发心衰相关(336例事件,P<1.7×10⁻⁴)。
  • V5时无心衰参与者(n=3908)中,83个心衰相关蛋白有48个与衰弱患病相关(223例,P<6.0×10⁻⁴),18个与V6新发衰弱相关(152例,P<1.0×10⁻³)。
  • 这些蛋白富集纤维化和炎症通路,与HFpEF的关联强于HFrEF。
  • 18个蛋白在CHS中均与衰弱患病和新发心衰相关。
  • 孟德尔随机化识别出数个蛋白对衰弱和心衰的潜在因果效应。

临床怎么用

  • 炎症和纤维化相关蛋白可能作为心衰与衰弱共病的潜在干预靶点。
  • 蛋白标志物或有助于识别心衰和衰弱高风险个体,尤其是HFpEF风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Heart failure (HF) and frailty frequently coexist and may share a common pathobiology, although the underlying mechanisms remain unclear. Understanding these mechanisms may provide guidance for preventing and treating both conditions. OBJECTIVE: To identify shared pathways between incident HF and frailty in late life using large-scale proteomics. DESIGN, SETTING, AND PARTICIPANTS: In this cohort study, 4877 aptamers (Somascan v4) were measured among participants in the community-based longitudinal Atherosclerosis Risk In Communities (ARIC) cohort study at visit 3 (V3; 1993-1995; n = 10 638) and at visit 5 (V5; 2011-2013; n = 3908). Analyses were externally replicated among 3189 participants in the Cardiovascular Health Study (CHS). Data analysis was conducted from February 2022 to June 2023. EXPOSURES: Protein aptamers, measured at study V3 and V5. MAIN OUTCOMES AND MEASURES: Outcomes assessed included incident HF hospitalization after V3 and after V5, prevalent frailty at V5, and incident frailty between V5 and visit 6 (V6; 2016-2017; n = 4131). Frailty was assessed using the Fried criteria. Analyses were adjusted for age, gender, race, field center, hypertension, diabetes, smoking status, body mass index, estimated glomerular filtration rate, prevalent coronary heart disease, prevalent atrial fibrillation, and history of myocardial infarction. Mendelian randomization (MR) analysis was performed to assess potential causal effects of candidate proteins on HF and frailty. RESULTS: A total of 4877 protein aptamers were measured among 10 638 participants at V3 (mean [SD] age, 60 [6] years; 4886 [46%] men). Overall, 286 proteins were associated with incident HF after V3 (822 events; P < 1.0 × 10-5), 83 of which were also associated with incident after V5 (336 events; P < 1.7 × 10-4). Among HF-free participants at V5 (n = 3908; mean [SD] age, 75 [5] years; 1861 [42%] men), 48 of 83 HF-associated proteins were associated with prevalent frailty (223 cases; P < 6.0 × 10-4), 18 of which were also associated with incident frailty at V6 (152 cases; P < 1.0 × 10-3). These proteins enriched fibrosis and inflammation pathways and demonstrated stronger associations with incident HF with preserved ejection fraction (HFpEF) than HF with reduced ejection fraction. All 18 proteins were associated with both prevalent frailty and incident HF in CHS. MR identified potential causal effects of several proteins on frailty and HF. CONCLUSIONS AND RELEVANCE: In this study, the proteins associated with risk of HF and frailty enrich for pathways related to inflammation and fibrosis as well as risk of HFpEF. Several of these proteins could potentially contribute to the shared pathophysiology of frailty and HF.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Ramonfaur, Buckley, Arthur, et al. High Throughput Plasma Proteomics and Risk of Heart Failure and Frailty in Late Life. JAMA Cardiol. 2024. PMID: 38809565. doi:10.1001/jamacardio.2024.1178

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。